• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.

作者信息

Bartkova J, Lukas J, Strauss M, Bartek J

机构信息

Danish Cancer Society, Division for Cancer Biology, Copenhagen.

出版信息

Oncogene. 1995 Feb 16;10(4):775-8.

PMID:7862456
Abstract

Cyclin D1 is a cell cycle regulator essential for G1 phase progression and a candidate proto-oncogene whose deregulated expression has been implicated in pathogenesis of several types of cancer. We have examined expression of cyclin D1 in 212 primary tumours of five histogenetically distinct types by immunohistochemistry and found strong aberrant accumulation of the protein in 21%, and a moderate overabundance in further 25% of cases. While the abnormalities were more frequent in carcinomas of the breast, i.e. the cancer type known for cyclin D1 gene amplification, aberrant expression was also seen in significant subsets of colorectal cancers, soft tissue sarcomas, uterine carcinomas and malignant melanomas. Comparison of distinct stages of tumour progression showed concordant cyclin D1 patterns in the in situ vs invasive breast carcinoma components (n = 37) and between primary and metastatic lesions (n = 51) of several tumour types. The specificity of the immunohistochemical data was supported by immunoblotting analysis of tissue and tumour lysates, and the tumour-specific over-expression was confirmed by computer-assisted image analysis. These observations suggest that alterations of cyclin D1 expression represent a common feature of malignancies of diverse histogenesis and indicate that both the spectrum of tumour types and the frequency of cyclin D1 aberrations significantly exceed previous estimations based on genetic analyses.

摘要

相似文献

1
Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis.
Oncogene. 1995 Feb 16;10(4):775-8.
2
Deregulation of cyclin E and D1 in breast cancer is associated with inactivation of the retinoblastoma protein.乳腺癌中细胞周期蛋白E和D1的失调与视网膜母细胞瘤蛋白的失活有关。
Oncogene. 1997 Jan 23;14(3):295-304. doi: 10.1038/sj.onc.1200833.
3
Molecular and immunochemical analyses of RB1 and cyclin D1 in human ductal pancreatic carcinomas and cell lines.人胰腺导管癌及细胞系中RB1和细胞周期蛋白D1的分子与免疫化学分析
Mol Carcinog. 1996 Feb;15(2):85-95. doi: 10.1002/(SICI)1098-2744(199602)15:2<85::AID-MC1>3.0.CO;2-Q.
4
Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer.人类头颈癌中D型细胞周期蛋白表达及G1期调控的异常模式
Cancer Res. 1995 Feb 15;55(4):949-56.
5
Cyclin D1 gene expression in human cervical neoplasia.细胞周期蛋白D1基因在人类宫颈肿瘤中的表达
Mod Pathol. 1996 Apr;9(4):418-25.
6
Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines.细胞周期蛋白D1在人类肿瘤细胞系中呈振荡变化,对细胞周期进程至关重要。
Oncogene. 1994 Mar;9(3):707-18.
7
Determination of the prognostic value of cyclin D1 overexpression in breast cancer.细胞周期蛋白D1过表达在乳腺癌中的预后价值测定。
Oncogene. 1995 Sep 7;11(5):885-91.
8
Expression patterns of cyclins D1, E in laryngeal epithelial lesions: correlation with other cell cycle regulators (p53, pRb, Ki-67 and PCNA) and clinicopathological features.细胞周期蛋白D1、E在喉上皮病变中的表达模式:与其他细胞周期调节因子(p53、pRb、Ki-67和PCNA)及临床病理特征的相关性
J Exp Clin Cancer Res. 2004 Jun;23(2):277-83.
9
Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression.大鼠成纤维细胞中细胞周期蛋白D1的过表达会导致生长控制、细胞周期进程和基因表达异常。
Oncogene. 1993 Dec;8(12):3447-57.
10
The PRAD-1/cyclin D1 oncogene product accumulates aberrantly in a subset of colorectal carcinomas.
Int J Cancer. 1994 Aug 15;58(4):568-73. doi: 10.1002/ijc.2910580420.

引用本文的文献

1
The Next Chapter in Cancer Diagnostics: Advances in HPV-Positive Head and Neck Cancer.癌症诊断的新篇章:HPV 阳性头颈部癌症的进展。
Biomolecules. 2024 Jul 30;14(8):925. doi: 10.3390/biom14080925.
2
Current and Emerging Diagnostic, Prognostic, and Predictive Biomarkers in Head and Neck Cancer.头颈癌当前及新出现的诊断、预后和预测生物标志物
Biomedicines. 2024 Feb 10;12(2):415. doi: 10.3390/biomedicines12020415.
3
Aberrant Cyclin D1 splicing in cancer: from molecular mechanism to therapeutic modulation.癌组织中细胞周期蛋白 D1 剪接异常:从分子机制到治疗调控。
Cell Death Dis. 2023 Apr 6;14(4):244. doi: 10.1038/s41419-023-05763-7.
4
Nuclear Epidermal Growth Factor Receptor Overexpression as a Survival Predictor in Oral Squamous Cell Carcinoma.核表皮生长因子受体过表达可作为口腔鳞状细胞癌的生存预测指标。
Int J Mol Sci. 2023 Mar 18;24(6):5816. doi: 10.3390/ijms24065816.
5
Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.雌激素受体阳性乳腺癌:利用涉及内分泌抵抗的信号通路。
Oncologist. 2018 May;23(5):528-539. doi: 10.1634/theoncologist.2017-0423. Epub 2018 Jan 19.
6
Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.在癌症治疗中抑制 CDK:当前证据和未来方向。
Target Oncol. 2018 Feb;13(1):21-38. doi: 10.1007/s11523-017-0541-2.
7
Lithocholic Acid Hydroxyamide Destabilizes Cyclin D1 and Induces G/G Arrest by Inhibiting Deubiquitinase USP2a.石胆酸羟酰胺通过抑制去泛素化酶USP2a使细胞周期蛋白D1不稳定并诱导G/G期阻滞。
Cell Chem Biol. 2017 Apr 20;24(4):458-470.e18. doi: 10.1016/j.chembiol.2017.03.002. Epub 2017 Mar 23.
8
PAC down-regulates estrogen receptor alpha and suppresses epithelial-to-mesenchymal transition in breast cancer cells.PAC下调雌激素受体α并抑制乳腺癌细胞的上皮-间质转化。
BMC Cancer. 2016 Jul 27;16:540. doi: 10.1186/s12885-016-2583-8.
9
Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.细胞周期蛋白D1通过限制细胞周期蛋白A/B依赖性的BRCA2磷酸化来促进BRCA2与Rad51的相互作用。
Oncogene. 2016 Jun 2;35(22):2815-23. doi: 10.1038/onc.2015.354. Epub 2015 Sep 21.
10
The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma.细胞周期蛋白D1表达在头颈部鳞状细胞癌中的预后价值。
Eur Arch Otorhinolaryngol. 2016 Apr;273(4):801-9. doi: 10.1007/s00405-014-3426-3. Epub 2014 Dec 12.